Tau Oligomers and Fibrils Exhibit Differential Patterns of Seeding and Association With RNA Binding Proteins

Lulu Jiang†, Jian Zhao‡, Ji-Xin Cheng²,³ and Benjamin Wolozin¹,3,4,5

¹ Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, United States; ² Boston University Photonics Center, Boston, MA, United States; ³ Center for Neurophotonics, Boston University School of Medicine, Boston, MA, United States; ⁴ Department of Neurology, Boston University School of Medicine, Boston, MA, United States; ⁵ Center for Systems Neuroscience, Boston University School of Medicine, Boston, MA, United States

INTRODUCTION

The microtubule association protein tau is one of the principal components of pathology in Alzheimer's disease and related disorders (ADRD) (1). Tau exists primarily in the axon under basal conditions, with smaller amounts in the dendritic arbor. However, stress induces phosphorylation of tau and localization to the somato-dendritic compartment (2, 3). As the stress persists, the tau begins to accumulate as oligomers and then fibrils, ultimately forming neurofibrillary tangles, which are a pathological hallmark of Alzheimer’s disease and other tauopathies.

Our understanding of the patterns and properties of tau aggregates has evolved steadily. In vitro studies showed that tau exhibits an intrinsic affinity for RNA, an anionic agent, and a tendency to fibrillize in the presence of anionic agents, including RNA, heparin sulfate, dextran sulfate, and arachidonic acid (4–6). Aggregation of purified tau with anionic agents
leads to an ordered assembly of tau into oligomers and then fibrils, with formation of oligomers thought to be rate limiting (7). However, the physiology of tau is quite different because stress induces phosphorylation of tau at proline directed serines and threonines, which accelerates oligomerization and subsequent fibrilization, and also leads to the somatodendritic accumulation of tau (8, 9).

Studies increasingly reveal remarkable differences in the properties of tau aggregates. The evidence showing that tau conformations differ among diseases is perhaps most evident in the multiple Cryo-EM studies that have been recently published, showing the structural differences among fibrils isolated from brains of subjects with Alzheimer’s disease, Pick’s disease, corticobasal disease, and chronic traumatic encephalopathy (10–14). Although tau fibrils are the pathological hallmarks of disease, some studies suggest that they are end-stage species that might not be the actual tau aggregate responsible for toxicity and neurodegeneration. Studies in transgenic mouse models of tauopathy demonstrate that neurofibrillary tangles do not induce degeneration on their own, and that neurons lacking neurofibrillary pathology exhibit more functional deficits than neurons containing neurofibrillary pathology (15–17).

Seeding and propagation studies provide a powerful means to compare the biological actions of different conformations of tau aggregates. Studies of tau propagation demonstrate the presence of strains of tau aggregates that differ in their pattern of propagation (18). Direct comparison of tau oligomers and fibrils using an in vivo propagation assay demonstrates that both species propagate robustly but that oligomeric tau (oTau) elicits much more neurodegeneration (19). This study also showed a striking association between tau oligomers and RNA binding protein (RBP) pathology (19).

Multiple studies demonstrate associations between tau and elements of RNA metabolism, including RBPs and ribosomal proteins (20–27). Tau binds to ribosomal proteins (23, 24, 28). Tau plays a role in the nucleolus, possibly regulating ribosome biogenesis during stress (29). Tau regulates the formation of stress granules (SGs), which are an important element of the translational stress response, and reducing TIA1, a core SG nucleating RBP, delays progression in a mouse model of tauopathy (20, 21). The link between tau and stress is particularly important because stress induces hyperphosphorylation, oligomerization, and somatodendritic translation of tau, and stress is an inherent element of the disease process. In contrast, tau fibrilization evolves more slowly and is less tightly linked to physiological responses to stress. These observations support a hypothesis that species such as tau oligomers function as part of an integrated stress response and affect neurons in a manner that differs from tau fibrils.

The current study directly compares the actions of oTau and fibrillar tau (fTau) using a seeding assay in primary neuron cultures expressing human 4R0N tau (tau containing 4 repeats in the microtubule binding domain and 0 repeats in the amino-terminal domain). We find oTau and fTau elicit distinct patterns of tau inclusions in the neurons even though the exogenously applied oTau and fTau clear rapidly from the neurons. We also observe that oTau inclusions co-localize strongly with RBPs but exhibit little thioflavine S reactivity, whereas fTau inclusions co-localize strongly with thioflavine S reactivity but weakly with RBPs. These results point to a distinct biological activity of oTau.

**MATERIALS AND METHODS**

**Animals**

Use of all animals was approved by the Boston University Institutional and Animal Care and Use Committee. All animals were housed in an IACUC-approved vivarium at Boston University School of Medicine. Breeder of P301S/PS19 mice were obtained from the Jackson Lab (stock no. 008169). Generation F2 mice were bred in-house and aged to 9 months for experiment. Timed pregnant C57BL/6 were purchased from Charles River Laboratories and delivered at E-14, and then the postnatal P0 pups were used for primary hippocampal cultures.

**S1p and P3 Fractions Extraction From PS19 Brain Tissue**

The frozen hippocampus and cortex tissues (100–250 mg) were weighed and placed in a Beckman polycarbonate thick-wall centrifuge tube (cat no. 362305). A 10 × volume of homogenization buffer was then added to homogenize brain tissue with TBS buffer (50 mM Tris, pH 8.0, 274 mM NaCl, 5 mM KCl) supplemented with protease and phosphatase inhibitor cocktails (Roche, cat no. 05892791001 and cat no. 04906837001), as described previously (20). The homogenate was then ultracentrifuged at 28,000 rpm for 20 min at 4°C. After that, the supernatant was aliquoted to new microfuge tubes as S1 fraction (TBS-soluble). Then the pellet (P1 fraction) was homogenized with buffer B (10 mM Tris, pH 7.4, 800 mM NaCl, 10% sucrose, 1 mM EGTA, 1 mM PMSF), which was ∼5× volume of wet weight of the original tissue. The P1 homogenate was then ultracentrifuged at 22,000 rpm for 20 min at 4°C. Next, the supernatant (S2 fraction) was aliquoted to a new Beckman polycarbonate thick-wall tube and incubated with 1% Sarkosyl rotating in the bench top thermomixer at 37°C for 1 h. After the incubation, the fraction mix was ultracentrifuged at 55,000 rpm for 1 h at 4°C. Then the sarkosyl-insoluble pellet (P3 fraction) was resuspended with 50 µL TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0). For the extraction of S1p fraction, the supernatant (S1) fractions were ultracentrifuged a second time at 55,000 rpm at 4°C for 40 min. The TBS-extractable pellet (S1p) fractions were then resuspended in 4 × volume of TE buffer relative to the starting weight of the tissue homogenate.

The molecular weight of tau in these two fractions (S1p and P3) was documented by native polyacrylamide gel electrophoresis as described previously (19). Briefly, the concentration of total tau was measured by immunoblot using 3–12% reducing SDS-PAGE gel by comparison with gradient concentrations of recombinant tau ladders, using the tau-5 antibody (detecting total tau) by immunoblot. All the fractions were then normalized and divided into fractions of 20 µg/ml tau for storage and future use.
Primary Hippocampal Culture With P0 Pups

The sterilized 12-mm coverslips were placed into each well of a 24-well plate and then coated with 1 mg/ml poly-D-lysine for 1 h at room temperature in the culture hood. Then the plates were washed three times with sterile biology-grade water and dried in hood overnight. For the dissection of hippocampus from P0 pups, the pups were anesthetized via hypothermia by wrapping in gauze and placing in aluminum foil pouch on ice. After the brain was isolated from the skull, the meninges need to be completely removed from the brain tissue and unfurl the hippocampus. Then all the hippocampi were transferred into 15-ml conical tubes with 5 ml 0.25% Trypsin–EDTA supplemented with 150 µl DNase. The brain tissue was incubated in a 37 °C water bath for 15 min before being resuspended and triturated in 2 ml plating medium (MEM Gibco no. 11090, 2.5% FBS, 1× penicillin/streptomycin, 1-glutamine, 0.6% D-glucose). Then the cells were passed through a 70-µm cell strainer before cell count. A total of 60,000 cells/cover slip were plated in 80 µl medium (7.5 × 10^5 cells/ml) for a 24-well plate. Thirty minutes later, 1 ml of feeding medium (Neurobasal media, 1 × B27...
Jiang et al. Tau Oligomers Colocalize With TIA1

FIGURE 2 | oTau seeds propagate into small tau inclusions while fTau seeds propagate into large tau inclusions. (A,B) The hippocampal neurons were treated with oTau (S1p) or fTau (P3) fractions for 24 h. Co-labeling of human tau (V5 tagged, red) in recipient neurons and the oligomeric tau marker TOMA2 (green) showed that

(Continued)
supplement, 1 × penicillin/streptomycin, 1 × L-glutamine) was added into each well.

**Cell Transduction**

For cell transduction, at day 2 of cell culture, neurons were transduced with AAV1 vectors of human 4R0N WT tau at MOI 200. The culture medium was replaced ~1/2 volume of feeding media every 3–4 days for cell maintenance until ready to use for experiment on days 14 to 21.

**oTau (S1p) and fTau (P3) Fraction Treatments**

S1p and P3 stock solution (20 µg/ml) were diluted in feeding medium for each well in 24-well plates and added into the cells by completely replacing the old medium. Then the cells were fixed by 4% PFA or snap frozen in a time series (3, 24, 48, 96 h) for further analysis.

**Immunofluorescence Labeling of Fixed Primary Culture**

Cells on a 24-well coverslip were fixed with 0.5 ml 4% paraformaldehyde (PFA)/phosphate buffered saline (PBS) for 15 min followed by washing three times in PBS. The cells were then permeabilized in 0.5 ml PBS/0.1% Triton X-100 (PBST) for 15–30 min. Blocking was done in 0.5 ml of 5% bovine serum albumin (BSA)—5% donkey serum in PBST for 1 h. The primary antibodies were diluted in 5% BSA/PBST and incubated with the cells overnight at 4 °C. On the 2nd day, the neurons were continued to be incubated in secondary antibodies, which were diluted in 5% BSA/PBST, for 2 h at room temperature (RT). All the secondary antibodies were purchased from Thermo Fisher Scientific made in donkey and used for 1:800 dilution in labeling. After secondary antibody, cells were incubated in DAPI diluted 1:10,000 in PBST (5 mg/ml stock solution) for 5 min after first wash. After washing three times with PBS, coverslips were mounted onto glass microscope slides using 8–10 µl Prolong Gold Antifade mounting media (Thermo Fisher Scientific, cat no. P36930) per coverslip. Slides were naturally dried in fume hood (or stored at 4°C until ready to dry in fume hood). The primary antibodies used in this study for immunocytochemistry are as follows: MAP-2 (chicken, AVES, MAP 1: 250), MAP-2 (rabbit, Millipore, AB5622, 1:1000), V5 (rabbit, Sigma-Aldrich, V8137, 1:1000), CP-13 (mouse, provided by Peter Davies, 1:300), TIA1 (rabbit, Abcam, ab40693, specifically lot no. GR3202325-1, 1:400), PABP (rabbit, Abcam, ab21060, 1:400), EIF3n (rabbit, Santa Cruz, sc-137214, 1:400), p62 (rabbit, Thermo Fisher Scientific, PA5-27247, 1:400), TOMA2 (mouse, provided by Dr. Rakez Kayed, 1:300), and Tau13 (mouse, provided by Dr. Nicholas M. Kanaan from Michigan State University, 1:1000).

Images were captured by a Zeiss Axio Observer microscope in Figures 1, 3, 5. Images were captured by Zeiss LSM700 confocal microscope in Figures 2, 4.

**Immunoblot**

For p62 detection in primary culture, cell lysates were collected from frozen cultures with RIPA lysis buffer. Then 40 µg of reducing and non-reducing protein samples was separated by gel electrophoresis and transferred to 0.2-µm nitrocellulose membranes using the Bolt SDS-PAGE system (Life Technologies). Membranes were blocked in 5% non-fat dry milk in PBS supplemented with 0.025% Tween-20 (PBST) for 1 h at RT, followed by incubation overnight at 4°C in primary antibody diluted in 5% BSA/PBST. Primary antibodies used were as follows: Tau13 (mouse, provided by Dr. Nicholas M. Kanaan from Michigan State University, 1:5000); Tau 5 (mouse, provided by Dr. Nicholas M. Kanaan from Michigan State University, 1:500); p62 polyclonal antibody (Invitrogen, cat no. PA5-27247); GAPDH polyclonal antibody (Thermo Fisher Scientific, cat no. PA1987). Membranes were then washed three times with PBST and incubated in horseradish peroxidase–conjugated secondary antibodies (Jackson ImmunoResearch) diluted in 1% BSA/PBST at RT for 1 h. After incubation in secondary antibody, membranes were washed three times in PBST and developed using SuperSignal West Pico Chemiluminescent ECL substrate (Thermo Fisher Scientific, cat no. 34080).

**Image Analysis**

To quantify Tau protein aggregates distribution as well as evaluate the colocalization of the Tau protein and the TIA1 stress granules, we developed a customized MATLAB program to process large amounts of immunofluorescence images automatically (Supplementary Figure 1). This algorithm takes the red-fluorescent image that mainly labels the Tau oligomers and fibrils, and has the MATLAB program process the imaging data according to the following procedures: (1) the single-color RGB image is converted to a grayscale image with a bit depth of 8; (2) the noisy background and features are filtered out through the thresholding and the morphological operation; (3) the grayscale image is then converted to a binary image, and the residual filament structures, mostly from the axons, are further removed from this binary image; (4) based on post-processed binary images above, the distribution of Tau protein locations and sizes are calculated, extracted, and exported into a Microsoft Excel file for further statistical analysis. For evaluation of the Tau protein/TIA1 (or PABP, EIF3n) stress granules colocalization, the algorithm processes...
the red-fluorescent images using the same program to obtain a post-processed binary image. The algorithm also converts the green-fluorescent images into another binary map. Then, the algorithm calculates the overlapping between these two binary images, which determines the percentage of colocalization. There are several predefined parameters applied in the MATLAB programs, which are optimized using iterative testing.

**Statistical Analysis**

Statistical analyses were performed using GraphPad Prism version 6.00 for Windows with two-sided α of 0.05. All group data are expressed as mean ± SEM. Column means were compared using one-way ANOVA with treatment as the independent variable. Also, group means were compared using two-way ANOVA with factors on genotype and fraction treatments, respectively. When ANOVA showed a significant difference, pairwise comparisons between group means were examined by Tukey, Dunnett, or uncorrected Fisher’s LSD multiple comparison test.

**RESULTS**

**Seeding of Exogenous Oligomeric Tau (oTau) and Fibrillar Tau (fTau) Fractions in Recipient Primary Neurons**

The experimental is shown in Figure 1A. We extracted the S1p (mainly containing oligomeric tau) and P3 fractions (mainly containing fibrillar tau) from PS19 P301S mice brain aged 9 months. The primary hippocampal neurons were plated on a 24-well plate and transduced with 4R0N human Tau AAV1 on day 2. Overexpression of the 4R0N human tau was utilized to create an abundant pool of endogenous tau that might facilitate propagation. On day 14 of cell culture when the neurons are mature, the cells were treated with S1p (oTau) or
FIGURE 4 | Co-localization of small tau inclusions with stress granules. (A) Representative images showing the co-localization of phosphorylated tau inclusions CP13 (red) with TIA1 granules (green) at 3 h after oTau, fTau, or vehicle treatment in hippocampal neurons overexpressing human 4R0N tau. Co-stained markers are MAP-2 (violet) for neuron and DAPI (blue) for nucleus. Scale bar 20 µm. (B) Pearson coefficient of correlation between CP13-positive tau with RBP TIA1 is graphed for (Continued)
P3 (fTau) fractions dosing from 10 to 80 ng, and harvested at the indicated time point for the experiment presented in this article (Figure 1A). Immunoblot with Tau5 and Tau13 antibody confirmed the expression of human tau in transfected C57 neurons (Figure 1B).

To detect the uptake of tau fractions by recipient neurons, the cells were fixed at 1 h after DyLight-488 conjugated tau oligomers or fibril fractions were introduced into the culture medium. The result showed that both oTau and fTau were effectively taken up by neurons (Figure 1C, green); immunocytochemistry with the anti-human tau antibody, Tau13, showed the physical relationship of the exogenous tau to the endogenous human 4R0N tau expressed in these neurons (Figure 1C, red). Next, we repeated the experiment but the primary hippocampal neurons were harvested after 24 h to characterize potential propagation of tau fractions in the recipient neurons. Tau was identified in these cultures by labeling with antibody to human tau (tau13) as well as antibody to a V5 tag, which is also present as part of the chimeric human 4R0N tau expressed in these neurons. Fluorescence from the exogenously applied DyLight-488 conjugated tau oligomers and fibrils had largely faded by 24 h after application (Figure 1D). However, at 24 h, both the S1p and P3-treated groups showed the appearance of abundant V5 positive tau inclusions, corresponding to endogenously produced V5 tagged human tau (Figure 1D). Hippocampal neuron cultures exposed to vehicle exhibited equally strong V5 labeling, but had very smooth labeling without the appearance of inclusions (Figure 1D).

We proceeded to test the dose–response relationship comparing the dose of exogenous tau applied (oTau or fTau) and the resulting level of inclusion formation within the neuron at 24 h. The area per cell covered by the granular tau inclusions at 24 h were quantified after treatment with 0, 10, 20, 40, and 80 ng of oTau or fTau (Figure 1E). For fTau, formation of intracellular tau granules increased up to the 40 ng dose but not beyond (Figure 1E), whereas formation of intracellular tau granules in response to oTau increased linearly at all doses (Figure 1E). Application of non-linear curve fitting by logistic growth analysis showed plateauing for the fTau binding curve, which suggests that the seeding of fTau is limited by the interaction with the rate-limiting binding site or receptor-mediated entry pathway. In contrast, seeding by oTau occurs through a mechanism involving either a high abundance binding site or an entry pathway that does not require binding to a specific receptor (Figure 1E).

oTau Fractions Seed Small Tau Inclusions While fTau Seed Large Tau Inclusions
We proceeded to compare the distribution of oligomeric, TOMA2-positive tau inclusions with fibrillar, ThioS-positive tau inclusion after exposure to oTau or fTau. The oTau-specific antibody TOMA2 was used to map the distribution of tau oligomers in the recipient neurons at 24 h after tau seeding of oTau or fTau (Figure 2A). V5 antibody was used to label the total tau expression and calculate the fraction of tau inclusions that were TOMA2 positive. These results showed that oTau seeded higher fraction TOMA2-positive tau oligomers than fTau (Figure 2B). Meanwhile, Thioflavine S and V5 co-labeling was performed to detect the fraction of tau inclusions that exhibited fibrillar tau (Figure 2C). These results showed that fTau fraction seeded a higher fraction of fibrillar tau than did oTau (Figure 2D).

We also quantified the size distribution of the tau inclusions in the recipient neurons after 24 h of oTau or fTau seeding. We observed that the number of tau inclusions induced by oTau was highest at the smallest diameters and steadily decreased with size (Figure 2E). In contrast, inclusion induction by fTau peaked at a larger size, with fewer inclusions at the very small or very large size range (Figure 2F).

oTau and fTau Displayed Distinctive Seeding Cycles in the Recipient Neurons
To determine the replication cycle of tau oligomers and fibrils in the recipient neurons, we seeded the neurons with 40 ng of oTau or fTau, which is a dose that produces similar levels of seeding at 24 h. We then harvested cells over a time course of 3, 24, 48, and 96 h after treatment. The hippocampal neurons were stained with CP13 antibody (pSer202 Tau) to identify the tau inclusions (Figure 3A). By quantifying the granular area in the individual neurons that were treated with oTau and fTau fractions, we found that the accumulation of fTau-induced inclusions plateaued after 48 h, while the accumulation of oTau-induced inclusions continued to grow past 48 h (Figure 3B).

Small oTau Inclusions Co-Localize to Stress Granules in the Recipient Neurons
Our previous studies found that RNA binding protein TIA1 appeared to stabilize oligomeric tau and reduce conversion into larger fibrillar tau tangles (20). Subsequent studies of tau propagation in vivo also suggested that oTau selectively co-localizes with RNA binding proteins (RBPs) linked to SGs,
Figure 5 | Co-localization of large tau inclusions with p62. (A) Immunoblotting detecting p62 expression in neurons after oTau or fTau treatment. Each lane represents an independent biological replicate. The immunoblotting was performed with cell lysate from hippocampal cultures overexpressing human 4R0N WT tau (Continued)
such as TIA1 (19). We preceded to quantitatively compare the association of oTau and fTau with RBPs and SGs in the hippocampal neuron seeding model. We quantified the co-localization of propagated tau with RBPs, including TIA1, PABP, and EIF3η. These RBPs are the key components of SGs which have been found to play important roles in the progression of neurodegenerative diseases (30). Hippocampal neurons overexpressing human 4R0N tau were seeded with oTau or fTau fractions (40 ng/well), and fixed at 3 h after treatment. The cells were co-labeled with antibodies to phospho-tau (CP13) and each RBP. In each case, the result showed stronger co-localization of cytoplasmic RBPs with inclusions induced by oTau than those induced with fTau (Figure 4). The results for TIA1 showed that oTau induced strong TIA1 translocation from the nucleus into neuronal soma and co-localization with oTau inclusions (Figures 4A,B); we also note an overall increase in TIA1 fluorescence intensity in neurons exposed to oTau and fTau. Co-labeling of CP13 with PABP also showed stronger co-localization with oTau-induced inclusions than with inclusions induced by fTau (Figures 4C,D). Labeling with EIF3η also showed the same trend as with PABP; EIF3η showed stronger co-localization with inclusions induced by oTau in neuronal soma than those induced by fTau (Figures 4E,F); we also note an overall increase in EIF3η fluorescence intensity in neurons exposed to oTau and fTau. These results indicate that RNA binding proteins co-localize with the oTau complex.

The Propagated Large Tau Inclusions Co-Localize to p62 Foci in the Recipient Neurons

Previous studies suggested that fibrillar tau aggregates are recognized by p62/SQSTM1, which are then shunted toward the autolysosomal cascade for degradation (31–33). The results presented earlier suggest that fTau induces large, fibrillar tau inclusions, whereas oTau induces smaller, non-fibrillar inclusions (Figure 3). Because p62 recognizes fibrillar aggregates, we hypothesized that the fibrillar inclusions stimulated by fTau might also be recognized by p62. To test this hypothesis, we harvested the hippocampal neurons at 24 and 96 h after oTau or fTau treatment. Quantification of p62 expression in total cell lysates by immunoblotting showed that there was significantly more p62 expression at 96 h in the neurons seeded with fTau than those seeded with oTau (Figures 5A,B). Next, we examined the degree of co-localization of p62 with tau inclusions at 96 h after seeding with oTau or fTau tau. p62 inclusions were strongly apparent in neurons seeded with either oTau or fTau, and were increased over vehicle-treated neurons (Figures 5C,D). Importantly, p62 was significantly more abundant and showed more co-localization with tau inclusions in neurons seeded with fTau than oTau (Figures 5C,D). These results support the hypothesis that tau inclusions induced by fTau have more fibrillar structures than those induced by oTau, leading to greater recognition by p62 and potentially promoting increased shunting through the autolysosomal cascade.

DISCUSSION

Protein aggregates show a strong propensity to seed and propagate in cell culture and in vivo. Although the morphological changes associated with varying conformers of these aggregates are easily documented, little is known about the biological activities of the varying conformers. In this study, we compared the morphological and biological characteristics of two types of tau aggregates, oTau and fTau. We used tau species generated from 9-month-old P301S tau mice because the oTau generated from these mice is associated with neurodegeneration and previously shown to be toxic (19). We also used primary cultures of hippocampal neurons expressing V5-tagged human tau to increase the rate of seeding and to distinguish between the exogenously applied tau species (that lack a V5 tag) and the endogenously generated tau species that contain a V5 tag. The exogenously applied oTau and fTau were both rapidly transported into the neurons in a dose-dependent manner, but then disappeared within 24 h, consistent with clearance of the exogenous species. In contrast, the resulting inclusions that formed showed labeling by the anti-V5 antibody, demonstrating that these inclusions were predominantly generated from endogenously produced 4R0N tau.

oTau and fTau exhibited striking differences in their uptake and the characteristics of the inclusions subsequently seeded. oTau showed a dose-dependent uptake that plateaued. Such a plateau is typically consistent with receptor binding and saturation of the binding site. Although we did not identify the binding site, a recent study suggests that the lipoprotein receptor LRP1 is an important mediator of tau propagation in vivo (34). LRP1 might also mediate uptake of oTau in neuron culture because it is also abundant in primary cultures of hippocampal neurons (35). The uptake of fTau did not exhibit plateauing at the doses used, although we cannot rule out plateauing at higher doses of fTau. The lack of plateauing might reflect uptake through
a non-specific mechanism, such as heparin sulfate proteoglycans, as has been reported previously. The differential uptake suggests different mechanisms of uptake between the two species, which has been noted for other aggregates, such as β-amyloid (36). Once taken up, oTau and fTau also elicited different types of inclusions, with the most abundant inclusions induced by oTau being smaller than those induced by fTau. Previous studies of tau seeding consistently noted differences in the morphological patterns of seeding associated with each strain of tau conformer (18, 37).

The biological basis for the differing behaviors of tau conformers is typically poorly understood, but in the current case the differential patterns might be linked to clear differences in the resulting processes associated with each type of aggregate. The inclusions induced by fTau were observed to label with ThioS and anti-p62 antibody. Such labeling indicates the presence of amyloids that are recognized by the cell and targeted by p62 to the autolysosomal system for degradation (38–40). The labeling by both ThioS and anti-p62 antibody supports the hypothesis that exogenous fTau seeds endogenous fTau. In contrast to the strong ThioS labeling, the seeded fTau inclusions exhibit relatively modest association with RBPs and SGs, which suggest that they have proportionately modest activity toward the translational stress response and RNA metabolism.

The behavior of oTau seeding contrasts sharply with that of fTau. Inclusions seeded by oTau showed much stronger association with RBPs associated with SGs, including TIA1, PABP, and EIF3η, than with ThioS and p62. This is consistent with previous work showing the association of tau with SGs in cells, in mice, and in human brain (19, 20, 23–28). Overexpressing tau induces SGs, whereas reducing tau appears to inhibit SG formation (21). Studies of mice with reduced TIA1 showed a surprising reduction in oTau but increase in fTau (20). The current study supports this putative linkage between oTau and SG biology, and is consistent with a role for tau in stimulating the translational stress response (30). It seems likely that tau phosphorylation by proline-directed stress kinases, such as GSK-3β, CDK5, and MARK/Par-1, represents an integrated part of this biological pathway. These kinases are all activated by stress, phosphorylation of tau by these kinases stimulates its oligomerization, and phosphorylated oligomeric tau occurs in concert with the translational stress response (9). Thus, tau phosphorylation, tau oligomerization, and the translational stress response are all linked and integrated.

A major question that remains to be definitively answered is causation. Tau oligomerization could result as an unintended byproduct of stress response or could occur as a biological process designed to drive the stress response. It is noteworthy that oligomerization is a normal common biological process that drives many signaling pathways. For instance, oligomerization is a necessary part in the activation of the proteins p53 and p62 (40–43). However, disease-related accumulation of tau oligomers might stimulate the translational stress response as an indirect response to toxicity induced by tau oligomers. Experiments showing that tau reduction protects against β-amyloid toxicity represent a partial step suggesting a biological role for tau in modulating stress, but more work must be done to rigorously determine whether oligomerization of tau presents a bona fide biological function or an unintended toxic byproduct.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article/Supplementary Material.

**ETHICS STATEMENT**

The studies involving animals were reviewed and approved by the Boston University Institutional and Animal Care and Use Committee.

**AUTHOR CONTRIBUTIONS**

LJ and JZ performed the experiments and helped write, conceptualized, and edited the article. J-XC conceptualized and edited the article. BW conceptualized, helped write, and edited the article. All authors contributed to the article and approved the submitted version.

**FUNDING**

We would like to thank the following funding agencies for their support: BW: NIH (AG050471, NS089544, AG056318, AG064932 and AG061706), J-XC: NIH (R35GM136223), and the BrightFocus Foundation.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.579434/full#supplementary-material

---

**REFERENCES**

1. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci. (2007) 8:663–72. doi: 10.1038/nrn2194

2. Zempel H, Mandelkow E. Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends Neurosci. (2014) 37:721–32. doi: 10.1016/j.tins.2014.08.004

3. Christensen KR, Beach TG, Serrano GE, Kanaan NM. Pathogenic tau modifications occur in axons before the somatodendritic compartment in mossy fiber and Schaffer collateral pathways. Acta Neuropathol Commun. (2019) 7:29. doi: 10.1186/s40478-019-0675-9

4. Friedhoff P, Schneider A, Mandelkow EM, Mandelkow E. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry. (1998) 37:10223–30. doi: 10.1021/b090353d
5. Kampers T, Friedhoff P, Biernaut J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated tau protein into Alzheimer-like paired helical filaments. FEBS Lett. (1996) 399:34–9. doi: 10.1016/S0014-5793(96)01386-5

6. Wilson DM, Binder LI. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer’s disease. Am J Pathol. (1997) 150:2181–95.

7. Dobson CM. Protein folding and misfolding. Nature. (2003) 426:884–90. doi: 10.1038/nature02261

5. Kampers T, Friedhoff P, Biernaut J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated tau protein into Alzheimer-like paired helical filaments. FEBS Lett. (1996) 399:34–9. doi: 10.1016/S0014-5793(96)01386-5

6. Wilson DM, Binder LI. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer’s disease. Am J Pathol. (1997) 150:2181–95.

7. Dobson CM. Protein folding and misfolding. Nature. (2003) 426:884–90. doi: 10.1038/nature02261

5. Kampers T, Friedhoff P, Biernaut J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated tau protein into Alzheimer-like paired helical filaments. FEBS Lett. (1996) 399:34–9. doi: 10.1016/S0014-5793(96)01386-5

6. Wilson DM, Binder LI. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer’s disease. Am J Pathol. (1997) 150:2181–95.

7. Dobson CM. Protein folding and misfolding. Nature. (2003) 426:884–90. doi: 10.1038/nature02261
42. Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, et al. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. *Nature.* (2013) 500:93–7. doi: 10.1038/nature12287

43. Nguyen TV, Yao S, Wang Y, Rolfe A, Selvaraj A, Darman R, et al. The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity. *J Biol Chem.* (2019) 294:16966–77. doi: 10.1074/jbc.RA119.010126

**Conflict of Interest:** BW is Co-founder and Chief Scientific Officer for Aquinnah Pharmaceuticals Inc. 

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Jiang, Zhao, Cheng and Wolozin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*